Roivant Sciences Ltd
ROIV22.410USD
+0.620+2.85%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
15.46BMarket Cap
LossP/E TTM
More Details of Roivant Sciences Ltd Company
Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis and cutaneous sarcoidosis; IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.
Roivant Sciences Ltd Info
Ticker SymbolROIV
Company nameRoivant Sciences Ltd
IPO dateDec 03, 2020
CEOVenker (Eric)
Number of employees750
Security typeOrdinary Share
Fiscal year-endDec 03
Address7Th Floor, 50 Broadway
CityLONDON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeSW1H 0DB
Phone4412955950
Websitehttp://roivant.com/
Ticker SymbolROIV
IPO dateDec 03, 2020
CEOVenker (Eric)
Company Executives of Roivant Sciences Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.76%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.34M
-0.52%
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
186.45K
-0.66%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
--
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
99.80K
+1.24%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
92.14K
+0.69%
Mr. Matthew Gline
Mr. Matthew Gline
Chief Executive Officer, Director
Chief Executive Officer, Director
82.26K
+4.20%
Ms. Melissa B. Epperly
Ms. Melissa B. Epperly
Independent Director
Independent Director
40.50K
+2.68%
Mr. Daniel Gold
Mr. Daniel Gold
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Frank M. Torti, M.D.
Dr. Frank M. Torti, M.D.
President and Vant Chairman
President and Vant Chairman
13.74M
--
Dr. Keith S. Manchester, M.D.
Dr. Keith S. Manchester, M.D.
Independent Director
Independent Director
1.93M
+0.76%
Dr. Eric Venker, M.D.
Dr. Eric Venker, M.D.
President and Immunovant Chief Executive Officer
President and Immunovant Chief Executive Officer
1.34M
-0.52%
Mr. Richard Pulik
Mr. Richard Pulik
Chief Financial Officer
Chief Financial Officer
186.45K
-0.66%
Ms. Jennifer Humes
Ms. Jennifer Humes
Chief Accounting Officer
Chief Accounting Officer
112.25K
--
Mr. Ilan Oren
Mr. Ilan Oren
Independent Chairman of the Board
Independent Chairman of the Board
99.80K
+1.24%
Revenue Breakdown
FY2025Q1
By BusinessUSD
Name
Revenue
Proportion
VTAMA
55.13M
0.00%
By RegionUSD
Name
Revenue
Proportion
United States
55.13M
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
VTAMA
55.13M
0.00%
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Dexcel Pharma Technologies, Ltd.
14.79%
Fidelity Management & Research Company LLC
8.73%
Ramaswamy (Vivek)
6.77%
Morgan Stanley Investment Management Inc. (US)
5.85%
SB Investment Advisers (UK) Limited
5.80%
Other
58.07%
Shareholders
Shareholders
Proportion
Dexcel Pharma Technologies, Ltd.
14.79%
Fidelity Management & Research Company LLC
8.73%
Ramaswamy (Vivek)
6.77%
Morgan Stanley Investment Management Inc. (US)
5.85%
SB Investment Advisers (UK) Limited
5.80%
Other
58.07%
Shareholder Types
Shareholders
Proportion
Investment Advisor
27.37%
Investment Advisor/Hedge Fund
19.48%
Hedge Fund
15.22%
Corporation
14.79%
Individual Investor
10.61%
Private Equity
9.04%
Research Firm
1.64%
Pension Fund
0.51%
Venture Capital
0.46%
Other
0.88%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
690
526.70M
77.13%
-109.19M
2025Q2
673
776.63M
112.42%
-147.35M
2025Q1
676
776.88M
113.63%
-136.03M
2024Q4
645
780.70M
109.07%
-147.12M
2024Q3
601
789.51M
107.30%
-83.47M
2024Q2
564
721.13M
95.89%
-110.95M
2024Q1
518
776.24M
96.43%
-47.46M
2023Q4
449
787.20M
97.95%
-13.44M
2023Q3
421
794.31M
100.15%
+12.61M
2023Q2
394
761.99M
100.91%
+10.72M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Dexcel Pharma Technologies, Ltd.
102.85M
15.06%
--
--
Jul 01, 2025
Fidelity Management & Research Company LLC
55.50M
8.13%
+3.83M
+7.41%
Jun 30, 2025
Ramaswamy (Vivek)
48.92M
7.16%
-1.78M
-3.50%
Sep 05, 2025
Morgan Stanley Investment Management Inc. (US)
33.37M
4.89%
+2.37M
+7.64%
Jun 30, 2025
SB Investment Advisers (UK) Limited
59.95M
8.78%
-1.90M
-3.07%
Jun 30, 2025
The Vanguard Group, Inc.
39.25M
5.75%
-1.44M
-3.53%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
35.53M
5.2%
-1.48M
-4.00%
Jun 30, 2025
QVT Financial LP
29.38M
4.3%
-36.41M
-55.34%
Jun 30, 2025
Viking Global Investors LP
34.24M
5.01%
-11.78M
-25.59%
Jun 30, 2025
Rubric Capital Management LP
20.37M
2.98%
+2.60M
+14.65%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco S&P MidCap 400 Pure Growth ETF
3.56%
Adaptiv Select ETF
2.91%
Virtus LifeSci Biotech Products ETF
2.79%
State Street SPDR S&P Biotech ETF
2.67%
WisdomTree US Value Fund
2.3%
ProShares Ultra Nasdaq Biotechnology
1.73%
Goldman Sachs Future Health Care Equity ETF
1.73%
Direxion Daily S&P Biotech Bull 3X Shares
1.41%
Invesco Nasdaq Biotechnology ETF
1.33%
WisdomTree BioRevolution Fund
1.3%
View more
Invesco S&P MidCap 400 Pure Growth ETF
Proportion3.56%
Adaptiv Select ETF
Proportion2.91%
Virtus LifeSci Biotech Products ETF
Proportion2.79%
State Street SPDR S&P Biotech ETF
Proportion2.67%
WisdomTree US Value Fund
Proportion2.3%
ProShares Ultra Nasdaq Biotechnology
Proportion1.73%
Goldman Sachs Future Health Care Equity ETF
Proportion1.73%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion1.41%
Invesco Nasdaq Biotechnology ETF
Proportion1.33%
WisdomTree BioRevolution Fund
Proportion1.3%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Roivant Sciences Ltd?
The top five shareholders of Roivant Sciences Ltd are:
Dexcel Pharma Technologies, Ltd. holds 102.85M shares, accounting for 15.06% of the total shares.
Fidelity Management & Research Company LLC holds 55.50M shares, accounting for 8.13% of the total shares.
Ramaswamy (Vivek) holds 48.92M shares, accounting for 7.16% of the total shares.
Morgan Stanley Investment Management Inc. (US) holds 33.37M shares, accounting for 4.89% of the total shares.
SB Investment Advisers (UK) Limited holds 59.95M shares, accounting for 8.78% of the total shares.
Dexcel Pharma Technologies, Ltd. holds 102.85M shares, accounting for 15.06% of the total shares.
Fidelity Management & Research Company LLC holds 55.50M shares, accounting for 8.13% of the total shares.
Ramaswamy (Vivek) holds 48.92M shares, accounting for 7.16% of the total shares.
Morgan Stanley Investment Management Inc. (US) holds 33.37M shares, accounting for 4.89% of the total shares.
SB Investment Advisers (UK) Limited holds 59.95M shares, accounting for 8.78% of the total shares.
What are the top three shareholder types of Roivant Sciences Ltd?
The top three shareholder types of Roivant Sciences Ltd are:
Dexcel Pharma Technologies, Ltd.
Fidelity Management & Research Company LLC
Ramaswamy (Vivek)
Dexcel Pharma Technologies, Ltd.
Fidelity Management & Research Company LLC
Ramaswamy (Vivek)
How many institutions hold shares of Roivant Sciences Ltd (ROIV)?
As of 2025Q3, 690 institutions hold shares of Roivant Sciences Ltd, with a combined market value of approximately 526.70M, accounting for 77.13% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -35.29%.
What is the biggest source of revenue for Roivant Sciences Ltd?
In FY2025Q1, the VTAMA business generated the highest revenue for Roivant Sciences Ltd, amounting to 55.13M and accounting for --% of total revenue.
